Drug WatchMonoclonal Antibodies Receive EUA to Treat Mild to Moderate COVID-19Aschenbrenner, Diane S. MS, RN Author Information Diane S. Aschenbrenner is an assistant professor at Notre Dame of Maryland University in Baltimore. She also coordinates Drug Watch: [email protected]. AJN, American Journal of Nursing: February 2021 - Volume 121 - Issue 2 - p 26 doi: 10.1097/01.NAJ.0000734112.15618.f4 Buy Metrics Abstract A combination of two monoclonal antibodies, casirivimab and imdevimab, has received emergency use authorization for the treatment of mild to moderate COVID-19. Casirivimab and imdevimab come in separate packages but must be combined into one IV infusion after dilution. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
